GlobeNewswire by notified

Inside information - BBS-Bioactive Bone Substitutes Plc: Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and RiverFort to strengthen the working capital position

Share

BBS-Bioactive Bone Substitutes Plc, Company announcement, inside information, 21 February 2024 at 10:30 am EET

Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and RiverFort to strengthen the working capital position

BBS-Bioactive Bone Substitutes Plc's (“BBS”, “the Company”) has signed the drawdown of the advance of EUR 500.000, pursuant to the terms and conditions of the Financing Agreement between BBS and RiverFort Global Opportunities Pcc Limited (“RiverFort”) signed and announced on September 30th 2021.

BBS settles the transaction fee of EUR 45,000 by the transfer of 74,915 treasury shares at the price of EUR 0.6007 per share. The reference price as agreed in the terms and conditions of the original agreement is the average of the daily VWAP for each the five consecutive trading day prior to the date of Advance (the “Reference Price”). Following the drawdown of the advance BBS will issue 416,195 warrants to RiverFort (with 0.8410 EUR subscription price (being 140% of the Reference Price) and a term of 48 months from grant).

After the transfers, BBS will have in total of 925 085 treasury shares.

For more information, please contact:

Juliusz Rakowski, CEO
+358 50 448 5132
juliusz.rakowski@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se

BBS in brief

BBS -Bioactive Bone Substitutes Plc is a orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Cortus Energy AB deltar på Nordbex projektlansering för satsning på koldioxidnegativ elproduktion i Nybro kommun den 18 april17.4.2024 08:00:00 CEST | Pressemelding

Stockholm, den 17 april 2024 PRESSMEDDELANDE Cortus Energy AB (”Cortus Energy” eller ”Bolaget”) deltar på projektlansering om koldioxidnegativ elproduktion, tillsammans med samarbetsparter Nordbex AB (”Nordbex”). Nordbex presenterar sin satsning och ambitionen att göra Nybro kommun koldioxidnegativ innan 2030 genom ett koldioxidnegativt kraftverk med Cortus Energys förgasningsteknologi, WoodRoll®. Under projektlanseringen kommer den svenska projektutvecklaren Nordbex presentera miljardsatsningen på koldioxidnegativ elproduktion som görs i Nybro kommun. Det första koldioxidnegativa kraftverket ska byggas av Nordbex, där Cortus WoodRoll®-förgasningsteknologi har en central roll till följd av den rena syngasen som produceras. Nordbex kraftverk kommer att generera 135 GWh ren energi och samla in 200 000 ton koldioxid från atmosfären varje år. Projektlanseringen inleds med en presentation av Nordbex, vilken går att följa live från och med kl 16:00 den 18 april på följande länk https://www.y

Norsk Hydro: Reminder - Invitation to Hydro's first quarter results 202417.4.2024 08:00:00 CEST | Press release

Hydro's first quarter results 2024 will be released at 07:00 CEST (01:00 EDT, 06:00 BST, 05:00 UTC/GMT) on Wednesday, April 24, 2024. The quarterly report and presentation will be available on hydro.com at the same time. President and CEO Hilde Merete Aasheim and Executive Vice President, Corporate Development & acting CFO Trond Olaf Christophersen will host a webcast in English at 08:30 CEST the same day. There will be a Q&A session directly after the presentation. There will be no presentation or press conference at our corporate headquarters. To join the webcast and ask questions, register your details in the webcast page. Once registered, you will receive a separate email confirming your registration. The webcast is powered by Livestorm. We advise that you investigate in advance if your company has any restrictions using this platform. Investor contact: Martine Rambøl Hagen +47 91708918 martine.rambol.hagen@hydro.com

Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS17.4.2024 08:00:00 CEST | Press release

Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeksThe twice-yearly, 10-minute SC injection has the potential to expand the usage of OCREVUS to treatment centres without IV infrastructure or with IV capacity limitationsU.S. FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024 Basel, 17 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from the Phase III OCARINA II study (S31.006) of OCREVUS® (ocrelizumab), an investigational twice-yearly, 10-minute subcutaneous (SC) injection. Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential benefits of this investigational formulation. Treat

Nilörn Interim Report Q1, 202417.4.2024 08:00:00 CEST | Press release

Period January - March Order intake increased by 5 percent to MSEK 233 (223)Revenue increased by 10 percent to MSEK 242 (221)Revenue adjusted for currency effects amounted to MSEK 243 (221), i.e., an underlying organic increase of 10 percentOperating profit amounted to MSEK 22.5 (16.9)Net profit for the period amounted to MSEK 16.7 (11.1)Earnings per share amounted to SEK 1.46 (0.97)Net cash excluding IFRS 16 amounted to MSEK 8 (43) Significant during the quarter The board has decided to propose to the annual general meeting a dividend of SEK 1.00 (5.00) per share, equivalent to MSEK 11.4 (57.0)Nilorngruppen has initiated a strategic collaboration with Worldfavor, strengthening the Nilorn:CONNECT solution and offer to our customers on their journey towards the Digital Product Passport. A presentation will be held today 17/4 at 08.30 am CET, where the CEO presents the report. You can participate by register on the link below: Registration Form For further information about Nilörn, pleas

Nilörn Delårsrapport Q1, 202417.4.2024 08:00:00 CEST | Pressemelding

Perioden januari - mars Orderingången ökade med 5 procent till 233 (223) MSEKOmsättningen i SEK ökade med 10 procent till 242 (221) MSEKOmsättningen justerat för valutaeffekter uppgick till 243 (221) MSEK, dvs en underliggande organisk ökning om 10 procentRörelseresultatet uppgick till 22,5 (16,9) MSEKPeriodens resultat uppgick till 16,7 (11,1) MSEKResultatet per aktie uppgick till 1,46 (0,97) SEKNettokassan (exklusive IFRS16) uppgick till 8 (43) MSEK Väsentliga händelser under kvartalet Styrelsen har beslutat att föreslå årsstämman en utdelning om 1,00 (5,00) kronor per aktie, motsvarande 11,4 (57,0) MSEKNilörn har inlett ett strategiskt samarbete med Worldfavor, vilket stärker lösningen Nilörn:CONNECT och erbjudandet till våra kunder på deras resa mot det Digitala Produktpasset En presentation kommer hållas idag 17/4 kl. 08.30, där VD presenterar rapporten. Du kan delta genom att registrera dig på nedanstående länk: Registration Form För ytterligare information om Nilörn, kontakta: K

HiddenA line styled icon from Orion Icon Library.Eye